1. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014) Authors: Reckamp, Karen L.; Giaccone, Giuseppe; Camidge, D. Ross; Gadgeel, Shirish M.; Khuri, Fadlo R.; Engelman, Jeff A.; Koczywas, Marianna; Rajan, Arun; Campbell, Alicyn K.; Gernhardt, Diana; Ruiz‐Garcia, Ana; Letrent, Stephen; Liang, Jane; Taylor, Ian; O'Connell, Joseph P.; Jänne, Pasi A. Journal: Cancer Issue: Volume 120:Issue 8(2014) Page Start: 1145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014) Authors: Reckamp, Karen L.; Giaccone, Giuseppe; Camidge, D. Ross; Gadgeel, Shirish M.; Khuri, Fadlo R.; Engelman, Jeff A.; Koczywas, Marianna; Rajan, Arun; Campbell, Alicyn K.; Gernhardt, Diana; Ruiz‐Garcia, Ana; Letrent, Stephen; Liang, Jane; Taylor, Ian; O'Connell, Joseph P.; Jänne, Pasi A. Journal: Cancer Issue: Volume 120:Issue 8(2014) Page Start: 1145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. (June 2022) Authors: Minchom, Anna; Viteri, Santiago; Bazhenova, Lyudmila; Gadgeel, Shirish M.; Ou, Sai-Hong Ignatius; Trigo, José; Bauml, Joshua M.; Backenroth, Daniel; Bhattacharya, Archan; Li, Tracy; Mahadevia, Parthiv; Girard, Nicolas Journal: Lung cancer Issue: Volume 168(2022) Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. (February 2019) Authors: Gadgeel, Shirish M.; Lukas, Rimas V.; Goldschmidt, Jerome; Conkling, Paul; Park, Keunchil; Cortinovis, Diego; de Marinis, Filippo; Rittmeyer, Achim; Patel, Jyoti D.; von Pawel, Joachim; O'Hear, Carol; Lai, Catherine; Hu, Sylvia; Ballinger, Marcus; Sandler, Alan; Gandhi, Mayank; Fehrenbacher, Lou Journal: Lung cancer Issue: Volume 128(2019) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cancer is chronic but antimicrobial stewardship is iconic: A retrospective cohort of optimal antibiotic use in ambulatory oncology clinics. Issue 1 (2nd May 2023) Authors: Ho, Tiffany A.; Patterson, Katelyn M.; Gadgeel, Shirish M.; Kenney, Rachel M.; Veve, Michael P. Journal: Antimicrobial stewardship & healthcare epidemiology Issue: Volume 3:Issue 1(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. (December 2021) Authors: Bazhenova, Lyudmila; Minchom, Anna; Viteri, Santiago; Bauml, Joshua M.; Ou, Sai-Hong Ignatius; Gadgeel, Shirish M.; Trigo, José Manuel; Backenroth, Daniel; Li, Tracy; Londhe, Anil; Mahadevia, Parthiv; Girard, Nicolas Journal: Lung cancer Issue: Volume 162(2021) Page Start: 154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. COPD‐dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk. Issue 3 (12th December 2019) Authors: Watza, Donovan; Lusk, Christine M.; Dyson, Gregory; Purrington, Kristen S.; Wenzlaff, Angela S.; Neslund‐Dudas, Christine; Soubani, Ayman O.; Gadgeel, Shirish M.; Schwartz, Ann G. Journal: International journal of cancer Issue: Volume 147:Issue 3(2020) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Cyclooxygenase 2 inhibition in patients with non–small cell lung cancer: Is this still a valid target for therapy?. Issue 18 (29th May 2015) Authors: Gadgeel, Shirish M. Journal: Cancer Issue: Volume 121:Issue 18(2015) Page Start: 3197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. (June 2020) Authors: Peters, Solange; Shaw, Alice T.; Besse, Benjamin; Felip, Enriqueta; Solomon, Benjamin J.; Soo, Ross A.; Bearz, Alessandra; Gadgeel, Shirish M.; Lin, Chia-Chi; Kao, Steven; Seto, Takashi; Masters, Elizabeth T.; Abbattista, Antonello; Clancy, Jill S.; Thurm, Holger; Reisman, Arlene; Peltz, Gerson; ... Journal: Lung cancer Issue: Volume 144(2020) Page Start: 10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. (July 2019) Authors: Awad, Mark M.; Leonardi, Giulia C.; Kravets, Sasha; Dahlberg, Suzanne E.; Drilon, Alexander; Noonan, Sinead A.; Camidge, D. Ross; Ou, Sai-Hong I.; Costa, Daniel B.; Gadgeel, Shirish M.; Steuer, Conor E.; Forde, Patrick M.; Zhu, Viola W.; Fukuda, Yoko; Clark, Jeffrey W.; Jänne, Pasi A.; Mok, Tony;... Journal: Lung cancer Issue: Volume 133(2019) Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗